These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36219271)

  • 1. Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini.
    Kohler S; Dalal S; Hettema A; Matse S; Bärnighausen T; Paul N
    AIDS Behav; 2023 Apr; 27(4):1222-1233. PubMed ID: 36219271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human resource needs and costs for HIV pre-exposure prophylaxis provision in nurse-led primary care in Eswatini and opportunities for task sharing.
    Kohler S; Dalal S; Hettema A; Matse S; Bärnighausen T; Paul N
    Hum Resour Health; 2022 Oct; 20(1):75. PubMed ID: 36274118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PrEP uptake and delivery setting preferences among clients visiting six healthcare facilities in Eswatini.
    Inghels M; Kim HY; Tanser F; Hettema A; McMahon SA; Oldenburg CE; Matse S; Kohler S; Geldsetzer P; Bärnighausen T
    AIDS Behav; 2022 Oct; 26(10):3345-3355. PubMed ID: 35429309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Costs of Creatinine Testing in the Context of a HIV Pre-Exposure Prophylaxis Demonstration Project in Eswatini.
    Kohler S; Ndungwani R; Burgert M; Sibandze D; Matse S; Hettema A
    AIDS Behav; 2022 Mar; 26(3):728-738. PubMed ID: 34409570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project.
    Furukawa NW; Schneider JA; Coleman ME; Wiener JB; Shrestha RK; Smith DK
    Health Serv Res; 2020 Aug; 55(4):524-530. PubMed ID: 32196656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population.
    Geldsetzer P; Bärnighausen K; Hettema A; McMahon SA; Dalal S; Chase RP; Oldenburg CE; Kohler S; Chen S; Dlamini P; Mavuso M; Hughey AB; Matse S; Bärnighausen T
    Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative accounts of PrEP discontinuation from the general population in Eswatini.
    Bärnighausen K; Geldsetzer P; Matse S; Hettema A; Hughey AB; Dlamini P; Mavuso M; Fakudze D; Kahn K; Bärnighausen T; McMahon SA
    Cult Health Sex; 2021 Sep; 23(9):1198-1214. PubMed ID: 32633617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "We know this will be hard at the beginning, but better in the long term": understanding PrEP uptake in the general population in Eswatini.
    Bärnighausen K; Matse S; Hughey AB; Hettema A; Bärnighausen TW; McMahon SA
    AIDS Care; 2020 Feb; 32(2):267-273. PubMed ID: 31437021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It's hard for us men to go to the clinic. We naturally have a fear of hospitals." Men's risk perceptions, experiences and program preferences for PrEP: A mixed methods study in Eswatini.
    Berner-Rodoreda A; Geldsetzer P; Bärnighausen K; Hettema A; Bärnighausen T; Matse S; McMahon SA
    PLoS One; 2020; 15(9):e0237427. PubMed ID: 32966307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'This is mine, this is for me': preexposure prophylaxis as a source of resilience among women in Eswatini.
    Bärnighausen KE; Matse S; Kennedy CE; Lejeune CL; Hughey AB; Hettema A; Bärnighausen TW; McMahon SA
    AIDS; 2019 Jun; 33 Suppl 1():S45-S52. PubMed ID: 31397722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of implementing HIV pre-exposure prophylaxis at community-based clinics in Indonesia.
    Siregar AYM; Juwita MN; Hardiawan D; Akbar A; Rachman ZH; Haekal MDF; Marwah YS; Putri TA; Rakhmat FF; Pohan MN; Handayani M; Budiarty TI; Afriana N; Prabowo BR; Wisaksana R
    Trop Med Int Health; 2024 Jan; 29(1):13-22. PubMed ID: 37926554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector.
    Peebles K; Mugwanya KK; Irungu E; Odoyo J; Wamoni E; Morton JF; Ngure K; Bukusi EA; Mugo NR; Masyuko S; Mukui I; Baeten JM; Barnabas RV;
    BMC Health Serv Res; 2021 Aug; 21(1):823. PubMed ID: 34399736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider perspectives on service delivery modifications to maintain access to HIV pre-exposure prophylaxis during the COVID-19 pandemic: qualitative results from a PrEP implementation project in Kenya.
    Velloza J; Roche SD; Owidi EJ; Irungu EM; Dollah A; Kwach B; Thuo NB; Morton JF; Mugo N; Bukusi EA; O'Malley G; Ngure K; Baeten JM; Mugwanya KK;
    J Int AIDS Soc; 2023 Feb; 26(2):e26055. PubMed ID: 36739603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Person-centred, integrated non-communicable disease and HIV decentralized drug distribution in Eswatini and South Africa: outcomes and challenges.
    Goldstein D; Ford N; Kisyeri N; Munsamy M; Nishimoto L; Osi K; Kambale H; Minior T; Bateganya M
    J Int AIDS Soc; 2023 Jul; 26 Suppl 1(Suppl 1):e26113. PubMed ID: 37408477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stepped-wedge randomised trial on the impact of early ART initiation on HIV-patients' economic outcomes in Eswatini.
    Steinert JI; Khan S; Mlambo K; Walsh FJ; Mafara E; Lejeune C; Wong C; Hettema A; Ogbuoji O; Vollmer S; De Neve JW; Mazibuko S; Okello V; Bärnighausen T; Geldsetzer P
    Elife; 2020 Aug; 9():. PubMed ID: 32831169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct out-of-pocket expenditure of tuberculosis treatment in intensive phase in Kalutara District, Sri Lanka.
    Ranawaka N; Nandasena S; De Alwis S
    Indian J Tuberc; 2023 Jul; 70(3):315-318. PubMed ID: 37562906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men Who Used nPEP: A Longitudinal Analysis of Attendees at a Large Sexual Health Clinic in Montréal (Canada).
    Xia Y; Greenwald ZR; Milwid RM; Trottier C; Boissonnault M; Gaul N; Charest L; Landry G; N Zahedi N; Szabo J; Thomas R; Maheu-Giroux M
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):408-415. PubMed ID: 33136737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe.
    Mangenah C; Nhamo D; Gudukeya S; Gwavava E; Gavi C; Chiwawa P; Chidawanyika S; Muleya P; Taruberekera N; Madidi N; Ncube G; Bara H; Napierala S; Dunbar M; Hoke T; Kripke K; Cowan FM; Torjesen K; Terris-Prestholt F
    AIDS Behav; 2022 Jan; 26(1):161-170. PubMed ID: 34453240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.